Forest Laboratories Files Investor Presentation
July 29 2011 - 3:15PM
Business Wire
Forest Laboratories, Inc. (NYSE: FRX) (“Forest”) has filed a
presentation with the Securities and Exchange Commission (“SEC”) in
connection with the Company’s Annual Meeting of Shareholders to be
held on August 18, 2011. The presentation is available at
www.FRX2011annualmeeting.com and on the SEC’s website,
www.sec.gov.
The presentation outlines important facts for shareholders to
consider in connection with the upcoming director elections at the
Annual Meeting, including the following:
- Forest has a longstanding track record
of delivering strong top-line and bottom-line financial performance
and superior value for shareholders, including share appreciation
that has exceeded the S&P 500 and the AMEX Pharmaceutical Index
(DRG) over both short and long time periods.
- The Company has a history of
operational and commercial successes and has successfully managed
loss of exclusivity cycles. Forest efficiently deploys capital and
has maintained a disciplined R&D effort that has led to the
development of one of the deepest and most promising product
portfolios in the industry, including a total of nine new products
which have been launched or are expected to be launched by
2013.
- Forest’s slate of 10 director nominees
has a combination of complementary skill sets, including senior
executive experience in the healthcare and financial services
industries as well as legal and compliance expertise, which sets
them apart from Mr. Icahn’s four nominees. Forest’s nominees are
committed to serving in the best interests of all Forest
shareholders.
Forest also has filed with the SEC several letters of support
from industry partners and trade associations, including Ironwood
Pharmaceuticals, Merz, Almirall, PhRMA and the U.S. Chamber
Institute for Legal Reform. The letters are available at
www.FRX2011annualmeeting.com and on the SEC’s website,
www.sec.gov.
Forest urges shareholders to vote the WHITE card they have
received from Forest and to vote “FOR ALL” 10 of Forest’s nominees
to its Board of Directors. Shareholders can vote by telephone,
Internet or by signing, dating and returning the Company’s WHITE
proxy card. Forest urges shareholders NOT to sign any gold proxy
card sent to them by the Icahn Group. Even a withhold vote for
Icahn’s nominees on a gold proxy card will cancel any previous
proxy submitted by shareholders that voted “FOR ALL” the Company’s
nominees.
Forward Looking Information
Except for the historical information contained herein, this
document contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
statements involve a number of risks and uncertainties, including
the difficulty of predicting FDA approvals, the acceptance and
demand for new pharmaceutical products, the impact of competitive
products and pricing, the timely development and launch of new
products, changes in laws and regulations affecting the healthcare
industry and the risk factors listed from time to time in Forest
Laboratories’ Annual Reports on Form 10-K (including the Annual
Report on Form 10-K for the fiscal year ended March 31, 2011),
Quarterly Reports on Form 10-Q, and any subsequent SEC filings.
Important Additional Information
Forest Laboratories, its directors, director nominees and
certain of its executive officers may be deemed to be participants
in the solicitation of proxies from Forest shareholders in
connection with the matters to be considered at Forest
Laboratories’ 2011 Annual Meeting. On July 18, 2011, Forest
Laboratories filed its definitive proxy statement (as it may be
amended, the “Proxy Statement”) with the U.S. Securities and
Exchange Commission (the “SEC”) in connection with such
solicitation of proxies from Forest shareholders. FOREST
SHAREHOLDERS ARE STRONGLY ENCOURAGED TO READ THE PROXY STATEMENT
AND ACCOMPANYING PROXY CARD AS THEY CONTAIN IMPORTANT
INFORMATION. Detailed information regarding the identity of
participants, and their direct or indirect interests, by security
holdings or otherwise, is set forth in the Proxy Statement,
including Appendix B thereto. Shareholders can obtain the Proxy
Statement, any amendments or supplements to the Proxy Statement and
other documents filed by Forest Laboratories with the SEC for no
charge at the SEC’s website at www.sec.gov. Copies are also
available at no charge at Forest Laboratories’ website at
www.frx.com or by writing to Forest Laboratories at 909 Third
Avenue, New York, New York 10022.
This document refers to or contains certain
previously published material. Consent of the author and
publication has not been obtained to use the material as proxy
soliciting material.
If you have any questions, require
assistance with voting your WHITE proxy card,
or need additional copies of the proxy
materials, please contact:
MACKENZIE PARTNERS INC.
105 Madison Avenue
New York, NY 10016
frxproxy@mackenziepartners.com
(212) 929-5500 (Call Collect)
Or
TOLL-FREE (800) 322-2885
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2023 to Jul 2024